Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

Arjun Mittra, Geraldine H.O’ Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Lawrence Rubinstein, Lamin Juwara, Deborah Wilsker, Jiuping Ji, Brandon Miller, Tony Navas, Katherine V. Ferry-Galow, Andrea Regier Voth, Ting Chia Chang, Shahanawaz Jiwani, Ralph E. Parchment, James H. Doroshow, Alice P. Chen